10/18/2024

Janusmed sex and gender

Janusmed sex and gender – linezolid

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Linezolid

Linezolid

Class : C

Show all info

Print

Contact us

  1. Humphreys H, Fitzpatick F, Harvey BJ. Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant Staphylococcus aureus: are they real, do they matter and why?. Clin Infect Dis. 2015;61(11):1708-14.

  2. Westgeest AC, Lambregts MMC, Ruffin F, Korn RE, Webster ME, Kair JL et al. Female Sex and Mortality in Patients with Staphylococcus aureus Bacteremia: A Systematic Review and Meta-analysis. JAMA Netw Open. 2024;7(2):e240473.

  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Zyvox (linezolid). Drugs@FDA [www]. [updated 2000-04-18, cited 2024-06-25].

  4. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57(11):793-7.

  5. Burkhardt O, Borner K, von der Höh N, Köppe P, Pletz MW, Nord CE et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother. 2002;50(5):707-12.

  6. Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49(9):1071-8.

  7. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47(2):548-53.

  8. Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, Tobin C et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55(3):333-40.

  9. Food and Drug Administration (FDA). Drug label - Zyvox (linezolid). Drugs@FDA [www]. [updated 2024-06-27, cited 2024-08-15].

  10. Zyvoxid (linezolid). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-06-20, cited 2024-08-15]

  11. Food and Drug Administration (FDA). Medical review - Zyvox (linezolid). Drugs@FDA [www]. [updated 2001-11-20, cited 2024-06-25].

  12. Tsutsumi T, Imai S, Kashiwagi H, Sato Y, Sugawara M, Takekuma Y. Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study. Eur J Clin Pharmacol. 2022;78(2):279-286.

  13. Wasserman S, Brust JCM, Abdelwahab MT, Little F, Denti P, Wiesner L et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother. 2022;77(4):1146-1154.

  14. Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007-12.

  15. Niwa T, Suzuki A, Sakakibara S, Kasahara S, Yasuda M, Fukao A et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126-33.

  16. Cui D, Hu X, Shi L, Wang D, Chen G. Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: a retrospective study. J Chemother. 2023;35(5):404-410.

  17. Mao Y, Dai D, Jin H, Wang Y. The risk factors of linezolid-induced lactic acidosis: A case report and review. Medicine (Baltimore). 2018;97(36):e12114.

  1. Humphreys H, Fitzpatick F, Harvey BJ. Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant Staphylococcus aureus: are they real, do they matter and why?. Clin Infect Dis. 2015;61(11):1708-14.
  2. Westgeest AC, Lambregts MMC, Ruffin F, Korn RE, Webster ME, Kair JL et al. Female Sex and Mortality in Patients with Staphylococcus aureus Bacteremia: A Systematic Review and Meta-analysis. JAMA Netw Open. 2024;7(2):e240473.
  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Zyvox (linezolid). Drugs@FDA [www]. [updated 2000-04-18, cited 2024-06-25].
  4. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57(11):793-7.
  5. Burkhardt O, Borner K, von der Höh N, Köppe P, Pletz MW, Nord CE et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother. 2002;50(5):707-12.
  6. Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49(9):1071-8.
  7. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47(2):548-53.
  8. Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, Tobin C et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55(3):333-40.
  9. Food and Drug Administration (FDA). Drug label - Zyvox (linezolid). Drugs@FDA [www]. [updated 2024-06-27, cited 2024-08-15].
  10. Zyvoxid (linezolid). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-06-20, cited 2024-08-15]
  11. Food and Drug Administration (FDA). Medical review - Zyvox (linezolid). Drugs@FDA [www]. [updated 2001-11-20, cited 2024-06-25].
  12. Tsutsumi T, Imai S, Kashiwagi H, Sato Y, Sugawara M, Takekuma Y. Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study. Eur J Clin Pharmacol. 2022;78(2):279-286.
  13. Wasserman S, Brust JCM, Abdelwahab MT, Little F, Denti P, Wiesner L et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother. 2022;77(4):1146-1154.
  14. Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007-12.
  15. Niwa T, Suzuki A, Sakakibara S, Kasahara S, Yasuda M, Fukao A et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126-33.
  16. Cui D, Hu X, Shi L, Wang D, Chen G. Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: a retrospective study. J Chemother. 2023;35(5):404-410.
  17. Mao Y, Dai D, Jin H, Wang Y. The risk factors of linezolid-induced lactic acidosis: A case report and review. Medicine (Baltimore). 2018;97(36):e12114.